Primary information |
---|
Hemolytik ID | 3258 |
PMID | 23415044 |
YEAR | 2013 |
SEQUENCE | FLGFLKNLF |
LENGTH | 9 |
NAME | WT |
C-ter Modification | Free |
N-ter Modification | Free |
Linear/Cyclic | Linear |
Stereochemistry | L |
Modified Residues | None |
FUNCTION | Antiviral |
ACTIVITY | HC50 =137.9μg/ml |
RBCs SOURCE | Human |
Secondary information |
---|
Properties | Physico-Chemical details |
STRUCTURE | |
DSSP states | CCSSCCCCC |
SMILES | N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc1ccccc1)C(=O)O |
External Links |
---|
PDB exact | PDB partial | SP exact | SP partial | TrEMBL exact | TrEMBL partial | IEDB exact | IEDB partial |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
NA |
|
Reference Informaiton |
---|
ARTICLE | Design of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus. |
AUTHORS | Hong W,Zhang R,Di Z,He Y,Zhao Z,Hu J,Wu Y,Li W |
JOURNAL | Biomaterials. 2013 Apr;34(13):3511-22. doi: 10.1016/j.biomaterials.2013.01.075. Epub 2013 Feb 13. |